Brensocatib faces ICER spotlight with strong case for clinical and economic value
ICER pegs an ~$88K benchmark for brensocatib and spotlights evidence gaps shaping NCFB access.
HTA
Reimbursement Series: CMS and Europe Reimbursement Pathway Accelerates Innovation
In a transformative week for market access, the CMS and Europe reimbursement pathway expansion delivered several pivotal coverage and pricing decisions reshaping patient access across cardiovascular, hepatic, and oncology therapies. From CMS’s national determinations on breakthrough devices to European HTA approvals in rare disease and cancer, these developments underscore a growing transatlantic alignment between regulators … Read more
HAS Stroke Update Transforms Access on World Stroke Day
HAS strengthens stroke management for faster, equitable emergency care access.
NICE Secures Breakthrough HTA Decision for Prostate Cancer
NICE issues breakthrough HTA decision on Bayer’s prostate cancer therapy.
NICE accelerates breakthrough framework for complex liver diseases
NICE drives innovation, reshaping MASH evaluations with transformative guidance.